SUMMARY The safety and efficacy of intralesionally administered interferon alfa-2b were assessed in 1 1 patients suffering from condylomata acuminata for four to 10 months for whom application of podophyllum resin had proved unsuccessful. Three warts from each patient were injected with 106 IU interferon alfa-2b three times a week for three weeks. Treatment was followed by a 13 week observation period.
Condyloma acuminatum, or the genital wart, is a common sexually transmitted disorder that is characterised by papillomatous lesions occurring on the mucus membrane or skin of the external genitalia as well as in the perianal region. These tumours are known to be caused by a human papillomavirus (HPV), especially types 6, 11, 16, and 18.'-Evidence also exists of a strong association between HPV types 16 and 18 and the malignant transformation of condylomata in the vulva and cervix. 25 Treatment of genital viral warts has proved difficult despite the wide variety of ablative and chemical methods available, such as surgical excision, laser treatment, cryosurgery, electrocauterisation, use of antimitotic agents, and application of podophyllum resin. These methods of treatment are often painful, may cause unwanted side effects and scarring, and are often associated with recurrence.'67 No form of treatment has yielded consistently effective results.
In contrast, recent trials have indicated promising results after using human recombinant interferon. fully completed the trial. The one patient who withdrew had difficulty in complying with the frequency of treatment visits; he did not experience any side effects while receiving treatment.
The treated patients (seven men and three women) were aged 19 to 55 (mean 35) years. Before the trial, podophyllum resin treatment had been unsuccessfully applied for periods ranging from four to 10 months. Figure 1 shows the changes in wart area for each patient as well as the mean change during the trial. Intralesional injection of interferon alfa-2b resulted in a highly significant reduction (F value = 32.72; p < 0.0001) in the mean area of the treated condylomata, which decreased from 29 mm2 to 12 mm2 by day 21, and to 2-3 mm2 by week 16. The reduction in wart area was especially noteworthy between days 19 and 21 (p < 000001), 21 and 24 (p = 0 0069), and 24and 26 (p < 0o0001).
In six out of the 10 patients, both the test and control condylomata cleared completely (fig 2) . The test warts disappeared by day 24 (one patient), day 26 (three patients), between weeks four and seven (one patient), and between weeks seven and 12 (one patient). By contrast, the condylomata remained refractory in four patients (two men and two women). A relapse was observed in one woman: all her condylomata had cleared by day 26, but one lesion reappeared during the eighth week at a site that had been injected. In two patients (one man and one woman) condylomata that had shrunk in size began ' 
Discussion
In this study of 11 patients, the intralesional administration of interferon alfa-2b for three weeks proved to be effective in eliminating or reducing most of the genital warts treated, which confirms results from previous preliminary or double blind placebo controlled studies.'s A total cure, however, only occurred in five patients in whom the positive effects of treatment were maintained for 13 weeks after intralesional injection of the interferon preparation. One out of the six patients whose lesions had disappeared suffered a relapse during the study period.
Though adjacent warts were not measured, interferon treatment also seemed to reduce non-treated lesions next to the treated warts during and after interferon treatment. Further testing as to whether HPV might also be affected in the tissues adjacent to the lesions is warranted.
No serious or severe side effects attributable to interferon alfa-2b were reported by any ofthe patients. The reactions were generally characterised by mild influenza like symptoms, headache, or muscle pain, and did not interfere substantially with the patients' daily activities. None of the patients considered subcutaneous interferon injections with a fine needle (16 x 0O5 mm) to be inordinately painful.
Several different treatment regimens for intralesional and intramuscular administration of interferon alfa-2b have been used to treat condylomata acuminata, which have resulted in differing degrees of success. The results achieved have also depended on the duration of treatment and the length of the follow up period.`'5 Although the injection of interferon alfa-2b can be effective in treating genital warts, additional studies must be performed to optimise doses and treatment schedules. In the meantime, intralesional injection of interferon alfa-2b may be considered to be one of the possible treatments for this sexually transmitted disease.
